A FEASIBILITY STUDY OF CONCOMITANT BOOST RADIOTHERAPY FOR PATIENTS WITH CANCER OF THE SUPRAGLOTTIC LARYNX

被引:7
作者
BUJKO, K
SKOCZYLAS, JZ
BENTZEN, SM
HLINIAK, A
WASILEWSKI, M
SZUTKOWSKI, ZJ
OSMOLSKI, A
机构
[1] DANISH CANC SOC,DEPT EXPTL CLIN ONCOL,AARHUS,DENMARK
[2] POSTGRAD TEACHING MED CTR,DEPT ENT,WARSAW,POLAND
关键词
D O I
10.3109/02841869309092444
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between February 1988 and December 1989, 65 patients with supraglottic cancer completed a course of concomitant boost radiotherapy. Cases with N3 disease, a Karnovsky performance score less than 70, age above 70 years, or a second primary cancer were not eligible for the study. Distribution of the patients was: Stage T1-T2 30%, T3-T4 70%, NO 68%, N+ 32%. The total dose ranged from 60 Gy to 76 Gy (median 66 Gy); overall treatment time ranged from 36 to 56 days with a median of 42 days. The daily dose during the first 4 weeks was 1.8 Gy, and during the last 2 weeks it was 1.6 Gy b.i.d. with a 4- or (after September 1988) 6-h interval. The clinical impression was that the early mucosal reactions were acceptable but more severe than after conventional treatment, with confluent membranous mucosal reaction being observed in 54% of the patients. Also, this reaction was significantly more frequent in patients treated with a 4-h interval (68%) than with a 6-h interval (41%) between the daily fractions. To relieve severe dysphagia, narcotics were required in 22% of the patients. The follow-up time ranged from 22 to 50 months, median 34 months. Treatment-requiring late complications were observed in 8 patients, and the 3-year actuarial risk was 17% with 95% confidence limits (6%, 27%). Two of these patients had severe complications: one of them required a temporary tracheostomy due to arytenoid edema and the other developed a laryngo-cutaneous fistula which healed after pharmacological treatment. Actuarial 3-year local-regional control was 59% (46%, 71%) and 3-year actuarial crude survival 55% (42%, 67%). There was no significant difference in the incidence of late complications or tumor control between the two groups of patients treated with a 4- or 6-h interval between the daily fractions. This study shows that the concomitant boost regimen tried here is feasible, but also stresses that the interval between dose fractions should be 6 h or more.
引用
收藏
页码:637 / 640
页数:4
相关论文
共 8 条
[1]   CONCOMITANT BOOST RADIOTHERAPY SCHEDULES IN THE TREATMENT OF CARCINOMA OF THE OROPHARYNX AND NASOPHARYNX [J].
ANG, KK ;
PETERS, LJ ;
WEBER, RS ;
MAOR, MH ;
MORRISON, WH ;
WENDT, CD ;
BROWN, BW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06) :1339-1345
[2]  
FLETCHER G, 1973, TXB RADIOTHERAPY, P140
[3]  
JOHNSON CR, 1992, CANCER-AM CANCER SOC, V69, P2749, DOI 10.1002/1097-0142(19920601)69:11<2749::AID-CNCR2820691120>3.0.CO
[4]  
2-4
[5]   ACCELERATED FRACTIONATION RADIOTHERAPY FOR LARYNGEAL-CANCER, ACUTE, AND LATE TOXICITY [J].
KAANDERS, JHAM ;
VANDAAL, WAJ ;
HOOGENRAAD, WJ ;
VANDERKOGEL, AJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (03) :497-503
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]   CONCOMITANT BOOST RADIOTHERAPY FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
KNEE, R ;
FIELDS, RS ;
PETERS, LJ .
RADIOTHERAPY AND ONCOLOGY, 1985, 4 (01) :1-7
[8]   ACCELERATED FRACTIONATION IN THE RADIATION TREATMENT OF HEAD AND NECK-CANCER - A CRITICAL COMPARISON OF DIFFERENT STRATEGIES [J].
PETERS, LJ ;
ANG, KK ;
THAMES, HD .
ACTA ONCOLOGICA, 1988, 27 (02) :185-194